Affiliation: University of Oxford
- Diagnosing dementia: interrater reliability assessment and accuracy of the NINCDS/ADRDA criteria versus CERAD histopathological criteria for Alzheimer's diseaseE Hogervorst
University of Oxford, Oxford Project to Investigate Memory and Aging OPTIMA, Oxford, UK
Dement Geriatr Cogn Disord 11:107-13. 2000..An important finding was that the accuracy of diagnoses of AD made from the case notes alone was not different from the diagnoses obtained following active involvement with participants...
- Low free testosterone is an independent risk factor for Alzheimer's diseaseE Hogervorst
Oxford Project to Investigate Memory and Ageing, Department of Pharmacology, University of Oxford, Radcliffe Infirmary, Woodstock Rd, Oxford, OX2 6HE, UK
Exp Gerontol 39:1633-9. 2004..Lowering SHBG and/or screening for subclinical thyroid disease may prevent cognitive decline and/or wasting in men at risk for AD...
- Telephone word-list recall tested in the rural aging and memory study: two parallel versions for the TICS-MEva Hogervorst
Department of Geriatrics, Donald W Reynolds Center on Aging, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Int J Geriatr Psychiatry 19:875-80. 2004..We aimed to investigate the usefulness of three parallel versions of ten-item word list recall tasks administered by telephone...
- The controversy over levels of sex steroids in cases with Alzheimer's diseaseE Hogervorst
Department of Pharmacology, OPTIMA, University of Oxford, UK
J Neuroendocrinol 16:93-4. 2004
- Serum levels of estradiol and testosterone and performance in different cognitive domains in healthy elderly men and womenEva Hogervorst
Oxford Project to Investigate Memory and Ageing and the Department of Pharmacology, University of Oxford and Radcliffe Infirmary Trust, Oxford, OX2 6HE, UK
Psychoneuroendocrinology 29:405-21. 2004..More research is required to investigate whether there is a window of time in which hormone therapy could be beneficial for middle-aged men...
- Testosterone and gonadotropin levels in men with dementiaE Hogervorst
Oxford Project to Investigate Memory and Ageing, Department of Pharmacology, University of Oxford, Oxford, UK
Neuro Endocrinol Lett 24:203-8. 2003..We wanted to assess levels of pituitary gonadotropins that regulate sex steroid levels, to determine whether primary or secondary hypogonadism was responsible for low levels of testosterone in cases...
- The validity and reliability of 6 sets of clinical criteria to classify Alzheimer's disease and vascular dementia in cases confirmed post-mortem: added value of a decision tree approachE Hogervorst
Department of Pharmacology, Oxford Project to Investigate Memory and Ageing, University of Oxford, Oxford, UK
Dement Geriatr Cogn Disord 16:170-80. 2003..The DSM-IV and NINCDS-AIREN criteria for VaD showed poor validity and inter-rater reliability. We conclude that the forced use of decision trees through a computerized system enhances the accuracy of the clinical diagnoses of dementia...
- Measuring serum oestradiol in women with Alzheimer's disease: the importance of the sensitivity of the assay methodEef Hogervorst
Oxford Project to Investigate Memory and Ageing, University Department of Pharmacology, Oxford, UK
Eur J Endocrinol 148:67-72. 2003..Oestrogens could be protective against the development of Alzheimer's disease (AD) but reports on oestrogen levels in AD have been conflicting...
- Apolipoprotein E epsilon4 and testosterone interact in the risk of Alzheimer's disease in menE Hogervorst
Oxford Project to Investigate Memory and Ageing, Department of Pharmacology, Radcliffe, Infirmary, Oxford, UK
Int J Geriatr Psychiatry 17:938-40. 2002..To assess the association between testosterone levels and APOEepsilon4 in cases with AD and controls...
- Serum total testosterone is lower in men with Alzheimer's diseaseE Hogervorst
Oxford Project to Investigate Memory and Ageing, University Department of Pharmacology and the Radcliffe Infirmary Trust, Oxford, United Kingdom
Neuro Endocrinol Lett 22:163-8. 2001..The purpose of this study was to determine whether the level of serum total testosterone (TT) was different in cases of Dementia of the Alzheimer's Type (DAT) than in controls...
- The Hopkins Verbal Learning Test and screening for dementiaEva Hogervorst
University of Oxford, Oxford Project to Investigate Memory and Ageing, Oxford, UK
Dement Geriatr Cogn Disord 13:13-20. 2002..Unlike the MMSE, the HVLT has no ceiling effects and does not have to be adjusted for education. We conclude that the HVLT is an easy to administer, quick and well tolerated tool for the screening of dementia...
- The interaction of serum folate and estradiol levels in Alzheimer's diseaseEva Hogervorst
Oxford Project to Investigate Memory and Ageing, University Department of Pharmacology, Radcliffe Infirmary, Oxford, United Kingdom
Neuro Endocrinol Lett 23:155-60. 2002..We hypothesised that the lack of effect of ERT might be related to an interaction between estrogens and some other factor(s) associated with AD...
- Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer diseaseEva Hogervorst
Oxford Project to Investigate Memory and Ageing, Department of Pharmacology, University of Oxford and Radcliffe Infirmary Trust, Oxford OX2 6HE, England
Arch Neurol 59:787-93. 2002..The pathogenesis of leukoaraiosis on computed tomographic (CT) scanning is unknown, but cerebrovascular risk factors for leukoaraiosis show overlap with those for Alzheimer disease (AD)...
- Association of the androgen receptor CAG repeat polymorphism with Alzheimer's disease in menD J Lehmann
Oxford Project to Investigate Memory and Ageing, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK
Neurosci Lett 340:87-90. 2003..5, 95% confidence intervals: 1.2-5.0) in men, but not in women. This association appeared stronger in early-onset AD (< 65 years). We conclude that this AR polymorphism is of potential relevance to the risk of AD in men...
- The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysisE Hogervorst
Oxford Project to Investigate Memory and Ageing OPTIMA, Radcliffe Infirmary, Department of Pharmacology, University of Oxford, Woodstock Road, OX2 6HE, Oxford, UK
Neuroscience 101:485-512. 2000..g. education) and risk factors (e.g. smoking and apolipoprotein E genotype) for cognitive decline and Alzheimer's disease...
- Sensitivity and specificity of neuropsychological tests for mild cognitive impairment, vascular cognitive impairment and Alzheimer's diseaseC A De Jager
Department of Pharmacology, University of Oxford, Oxford Project to Investigate Memory and Ageing, Radcliffe Infirmary Trust, Oxford
Psychol Med 33:1039-50. 2003..We designed a brief comprehensive neuropsychological test battery to help differentiate control subjects from patients with mild cognitive impairment (MCI) and dementia...
- A new visual rating scale for white matter low attenuation on CTH K Mendes Ribeiro
Radcliffe Infirmary, Oxford, UK
Eur Neurol 45:140-4. 2001..CTs were read separately by 2 radiologists. Intraobserver reliabilities were 0.69 and 0.55, interobserver 0.70 (kappa values). Each assessment required only 1 min...
- Should surgical menopausal women be treated with estrogens to decrease the risk of dementia?Eef Hogervorst
Neurology 69:1070-1. 2007
- Thyroid function and cognitive decline in the MRC Cognitive Function and Ageing StudyEef Hogervorst
Department of Human Sciences, Brockington Building, Loughborough University, LE11 3TU Loughborough, UK
Psychoneuroendocrinology 33:1013-22. 2008..Treatment with thyroxine in those without thyroid disease (as is sometimes done in anti-ageing clinics) is thus not recommended on the basis of these data and the optimal therapeutic level in the elderly may be lower than is assumed...
- Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factorsRaj N Kalaria
Institute for Ageing and Health, Newcastle General Hospital, Newcastle upon Tyne, UK
Lancet Neurol 7:812-26. 2008..Dementia costs in developing countries are estimated to be US$73 billion yearly, but care demands social protection, which seems scarce in these regions...